Replies to post #36917 on PharmaCyte Biotech Inc (PMCB)

[rudygerner]

Novo Nordisk, Ely Lilly and Sanofi Aventis supply all the insulin sold in the United States: http://www.diabetesforecast.org/2013/jul/making-insulin.html

Those 'big three' companies are currently plundering the insulin market in the United States: http://insulinnation.com/treatment2/medicine-drugs/understanding-insulin-sticker-shock/
Another relevant link:http://www.rxrights.org/the-rising-price-of-insulin/


The world market is the grand prize:
http://www.marketsandmarkets.com/PressReleases/human-insulin.asp

All of the companies mentioned stand to lose a significant amount of future revenue due to a successful diabetes treatment which utilizes encapsulated Melligen cells to produce insulin - a treatment which requires no devices or immunosuppresive drugs (and no daily injections or pills to worry about, either). If 'ya can't beat 'em, join 'em. Or better yet, buy them. PharmaCyte Biotech's unique diabetes treatment will be the catalyst which induces a buyout, imo.

[Peacefulwendy]

Honestly rcstock, I don't know that we will get preclinical trial results. I would not hold my breath. If we move into Phase 1 as planned, that would be my signal that all is well. This is really a long term play here. I am new to biotechs. This is my first and I've been here over a year. Things have progressed much slower than I ever anticipated. Just being honest. What keeps me going is the past data results and all the key players involved as well as ongoing milestone accomplishments like Schedule 1 approval. It is easy for the company to come under attack when folks believe that something should happen but does not. The company has not promised preclinical results and I don't think they are required. So, I just don't want folks to be disappointed if results don't come in July. We may have to wait for human trials before we get results and those are really what will drive this company forward. JMO...